Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors
Dianthus Therapeutics (NASDAQ: DNTH) has appointed Simon Read, Ph.D. to its Board of Directors, while announcing Lonnie Moulder's transition from the Board. Dr. Read brings over 30 years of biopharmaceutical experience, most recently serving as CEO and founder of Mariana Oncology until its Novartis acquisition in 2024, and previously as CSO of Ra Pharma until its UCB acquisition in 2020.
Dr. Read's extensive background includes R&D leadership roles at major pharmaceutical companies and involvement in developing prominent immunology drugs like Rituxan® and Actemra®. He is currently Chairman of Ethyreal Bio's Board and a Fellow of the Royal Society of Medicine (UK). The company is advancing DNTH103 through clinical trials, with Phase 2 MaGic results expected in September.
Dianthus Therapeutics (NASDAQ: DNTH) ha nominato Simon Read, Ph.D. nel suo Consiglio di Amministrazione, annunciando contestualmente il passaggio di Lonnie Moulder fuori dal Board. Il dottor Read vanta oltre 30 anni di esperienza nel settore biofarmaceutico, avendo recentemente ricoperto il ruolo di CEO e fondatore di Mariana Oncology fino all'acquisizione da parte di Novartis nel 2024, e precedentemente come CSO di Ra Pharma fino all'acquisizione da parte di UCB nel 2020.
Il suo ampio background include ruoli di leadership in R&S presso grandi aziende farmaceutiche e la partecipazione allo sviluppo di importanti farmaci immunologici come Rituxan® e Actemra®. Attualmente è Presidente del Consiglio di Amministrazione di Ethyreal Bio e Fellow della Royal Society of Medicine (Regno Unito). L'azienda sta portando avanti le sperimentazioni cliniche di DNTH103, con i risultati della Fase 2 MaGic attesi per settembre.
Dianthus Therapeutics (NASDAQ: DNTH) ha nombrado a Simon Read, Ph.D. en su Junta Directiva, mientras anuncia la transición de Lonnie Moulder fuera del Consejo. El Dr. Read aporta más de 30 años de experiencia en biofarmacéutica, habiendo sido recientemente CEO y fundador de Mariana Oncology hasta su adquisición por Novartis en 2024, y anteriormente CSO de Ra Pharma hasta su adquisición por UCB en 2020.
Su amplia experiencia incluye roles de liderazgo en I+D en grandes compañías farmacéuticas y participación en el desarrollo de reconocidos medicamentos inmunológicos como Rituxan® y Actemra®. Actualmente es presidente de la Junta de Ethyreal Bio y miembro de la Royal Society of Medicine (Reino Unido). La compañía está avanzando con los ensayos clínicos de DNTH103, con resultados de la Fase 2 MaGic esperados para septiembre.
Dianthus Therapeutics (NASDAQ: DNTH)는 Simon Read, Ph.D.를 이사회에 임명했으며, 동시에 Lonnie Moulder의 이사회 이탈을 발표했습니다. Read 박사는 30년 이상의 바이오제약 경험을 보유하고 있으며, 최근에는 2024년 노바티스에 인수된 Mariana Oncology의 CEO 겸 창립자로 재직했으며, 이전에는 2020년 UCB에 인수된 Ra Pharma의 CSO로 활동했습니다.
그의 광범위한 경력에는 주요 제약사에서의 연구개발 리더십 역할과 Rituxan® 및 Actemra®와 같은 유명 면역학 약물 개발 참여가 포함됩니다. 현재 Ethyreal Bio 이사회의 의장이며 영국 왕립 의학회(Royal Society of Medicine) 펠로우입니다. 회사는 DNTH103의 임상 시험을 진행 중이며, 9월에 2상 MaGic 결과가 발표될 예정입니다.
Dianthus Therapeutics (NASDAQ : DNTH) a nommé Simon Read, Ph.D. à son conseil d'administration, tout en annonçant la transition de Lonnie Moulder hors du conseil. Le Dr Read apporte plus de 30 ans d'expérience dans le secteur biopharmaceutique, ayant récemment été PDG et fondateur de Mariana Oncology jusqu'à son acquisition par Novartis en 2024, et auparavant directeur scientifique (CSO) de Ra Pharma jusqu'à son acquisition par UCB en 2020.
Son parcours étendu inclut des postes de direction en R&D dans de grandes entreprises pharmaceutiques et la participation au développement de médicaments immunologiques majeurs tels que Rituxan® et Actemra®. Il est actuellement président du conseil d'administration d'Ethyreal Bio et membre de la Royal Society of Medicine (Royaume-Uni). La société fait progresser DNTH103 dans ses essais cliniques, avec les résultats de la phase 2 MaGic attendus en septembre.
Dianthus Therapeutics (NASDAQ: DNTH) hat Simon Read, Ph.D. in seinen Vorstand berufen und gleichzeitig den Übergang von Lonnie Moulder aus dem Board bekannt gegeben. Dr. Read bringt über 30 Jahre Erfahrung in der Biopharma-Branche mit, war zuletzt CEO und Gründer von Mariana Oncology bis zur Übernahme durch Novartis im Jahr 2024 und zuvor CSO von Ra Pharma bis zur Übernahme durch UCB im Jahr 2020.
Sein umfangreicher Hintergrund umfasst Führungsrollen in Forschung und Entwicklung bei großen Pharmaunternehmen sowie die Mitwirkung an der Entwicklung bekannter Immunologie-Medikamente wie Rituxan® und Actemra®. Derzeit ist er Vorsitzender des Vorstands von Ethyreal Bio und Fellow der Royal Society of Medicine (UK). Das Unternehmen führt klinische Studien zu DNTH103 durch, wobei die Ergebnisse der Phase-2-Studie MaGic im September erwartet werden.
- Appointment of highly experienced executive with >30 years in biopharmaceutical industry
- Dr. Read's successful track record of leading companies to acquisitions (Mariana Oncology to Novartis, Ra Pharma to UCB)
- Company has progressed from private preclinical stage to public company with three ongoing clinical trials
- Phase 2 MaGic trial results expected in September
- Loss of board member Lonnie Moulder, who was instrumental in company's growth since 2019
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry
Previously served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020
NEW YORK and WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Simon Read, Ph.D., to the Company’s Board of Directors. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experience. Dianthus also announced that Lonnie Moulder will transition from the Board of Directors.
“I am pleased to welcome Simon to the Dianthus Board of Directors. His wealth of experience leading biopharmaceutical companies and R&D organizations will be invaluable as Dianthus continues to advance its mid- and late-stage clinical programs,” said Alison Lawton, Chair of the Dianthus Therapeutics Board of Directors. “I would also like to thank Lonnie for his dedicated service to the Board. His perspective and support were instrumental during a period when Dianthus quickly grew from a private, preclinical stage company to a publicly traded company now with three ongoing clinical trials.”
“I have been extremely impressed with the Dianthus team’s ability to advance a potential best-in-class complement inhibitor with significant potential since our initial seed investment in 2019,” said Lonnie Moulder, Managing Member, Tellus BioVentures LLC and Founder, Chairman and CEO, Zenas BioPharma. “I wish continued success to Dianthus as I transition from the Board and remain confident in the team’s ability to transform the lives of patients living with severe autoimmune diseases.”
Dr. Read most recently served as CEO and founder of Mariana Oncology until its acquisition by Novartis and was Chief Scientific Officer at Ra Pharma until its acquisition by UCB Pharma. Prior to this, he held R&D leadership roles at GlaxoSmithKline, AstraZeneca and Roche/Genentech and worked on the clinical development of some of the most well-known drugs in the immunology area, including Rituxan® and Actemra®. Dr. Read is a Fellow of the Royal Society of Medicine (UK) and Chairman of the Board of Ethyreal Bio. He previously served on the Board of Triana Biomedicines and Oxstem Ltd (UK). He obtained his Ph.D. from University of Hertfordshire, studied Physiology at the University of Manchester in the UK, and has authored over 50 articles in peer reviewed journals.
“The Dianthus team has done an excellent job executing rapidly on its three clinical programs with DNTH103,” said Dr. Read. “This is an exciting time for the Company with Phase 2 MaGic results anticipated in September. I look forward to partnering with this exceptional team and Board of Directors as I see tremendous potential for DNTH103 as a best-in-class, differentiated therapy option for patients with severe neuromuscular conditions.”
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and prospects, including statements regarding the expectations or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to DNTH103, and any developments or results in connection therewith, including the target product profile and administration of DNTH103; the anticipated timing of the initiation and results from those studies and trials; expectations regarding the time period over which the Company’s capital resources are expected to be sufficient to fund its anticipated operations; and expectations regarding the market and potential opportunities for complement therapies, in particular with respect to DNTH103. The words “opportunity,” “potential,” “milestones,” “runway,” “will,” “anticipate,” “achieve,” “near-term,” “catalysts,” “pursue,” “pipeline,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.
Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of DNTH103 and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the development of DNTH103 or the Company's other compounds may take longer and/or cost more than planned, that the Company may be unable to successfully complete the clinical development of the Company’s compounds, that the Company may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company’s Annual Report on Form 10-K for the period ended December 31, 2024, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.
The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com
FAQ
Who is Simon Read and why did DNTH appoint him to the Board of Directors?
What are the upcoming catalysts for Dianthus Therapeutics (DNTH) in 2025?
How many clinical trials does Dianthus Therapeutics (DNTH) currently have ongoing?
What is DNTH103 being developed for?
Who is leaving the Dianthus Therapeutics (DNTH) Board of Directors?
